

## Recombinant Mouse VEGFR3/FLT4 Protein (Fc Tag)

Catalog No. PKSM040597

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Synonyms</b>	AI323512;Chy;Flt-4;VEGFR-3;VEGFR3
<b>Species</b>	Mouse
<b>Expression Host</b>	HEK293 Cells
<b>Sequence</b>	Met 1-Glu 775
<b>Accession</b>	P35917-1
<b>Calculated Molecular Weight</b>	112 kDa
<b>Observed molecular weight</b>	150&85&65 kDa
<b>Tag</b>	C-hFc
<b>Bioactivity</b>	1. Measured by its ability to bind human VEGF-D and mouse FIGF-His in functional ELISA. 2. Immobilized human VEGF-C at 10 µg/mL (100 µL/well) can bind mouse VEGFR3-Fc. The EC50 of mouse VEGFR3-Fc is 0.008 µg/mL.

### Properties

<b>Purity</b>	> 92 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 1.0 EU per µg of the protein as determined by the LAL method.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
<b>Reconstitution</b>	Please refer to the printed manual for detailed information.

### Data



> 92 % as determined by reducing SDS-PAGE.

### For Research Use Only

## Background

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.

## For Research Use Only